Fungal infections:

Indications for Terbinafine Tablets:

Onychomycosis of the toenail or fingernail due to tinea unguium.


250mg once daily for 6 weeks (fingernail) or 12 weeks (toenail).


Not established.


Chronic or active liver disease.


Onychomycosis: confirm diagnosis with nail specimen. Perform LFTs prior to and periodically during treatment. Discontinue if hepatic injury, progressive skin rash (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), taste/smell disturbances, severe neutropenia (neutrophils ≤1000 cells/mm3), thrombotic microangiopathy occur, or if lupus erythematosus is suspected. Monitor CBCs if immunodeficient. Renal impairment (CrCl <50mL/min). Pregnancy (Cat.B), nursing mothers: not recommended.

Pharmacologic Class:

Allylamine antifungal.


Antagonized by rifampin. May be potentiated by cimetidine or CYP2C9 and CYP3A4 inhibitors (eg, fluconazole, ketoconazole, amiodarone). May potentiate caffeine or drugs metabolized by CYP2D6 (eg, tricyclic antidepressants, SSRIs, beta-blockers). May antagonize cyclosporine.

Adverse Reactions:

Headache, diarrhea, rash, dyspepsia, liver enzyme abnormalities, pruritus, taste disturbances, nausea, abdominal pain, flatulence, urticaria; hepatotoxicity, depressive symptoms, smell disturbances.


Formerly known under the brand name Lamisil.

How Supplied:

Contact supplier